FI885279A0 - Menetelmä 2 3-sidoksen tunnistavan monoklonaalisen vasta-aineen valmistamiseksi ja vasta-ainetta tuottava hybridooma - Google Patents

Menetelmä 2 3-sidoksen tunnistavan monoklonaalisen vasta-aineen valmistamiseksi ja vasta-ainetta tuottava hybridooma

Info

Publication number
FI885279A0
FI885279A0 FI885279A FI885279A FI885279A0 FI 885279 A0 FI885279 A0 FI 885279A0 FI 885279 A FI885279 A FI 885279A FI 885279 A FI885279 A FI 885279A FI 885279 A0 FI885279 A0 FI 885279A0
Authority
FI
Finland
Prior art keywords
monoclonal antibody
hybridoma
bond
preparation
antibody
Prior art date
Application number
FI885279A
Other languages
English (en)
Swedish (sv)
Other versions
FI95043C (fi
FI95043B (fi
FI885279A (fi
Inventor
Yoshitaka Nagai
Hideki Yamamoto
Kinji Takada
Masayoshi Ito
Yoshiyasu Shitori
Original Assignee
Kanto Ishi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanto Ishi Pharma Co Ltd filed Critical Kanto Ishi Pharma Co Ltd
Publication of FI885279A0 publication Critical patent/FI885279A0/fi
Publication of FI885279A publication Critical patent/FI885279A/fi
Application granted granted Critical
Publication of FI95043B publication Critical patent/FI95043B/fi
Publication of FI95043C publication Critical patent/FI95043C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI885279A 1987-11-17 1988-11-15 Menetelmä 2 3-sidoksen tunnistavan monoklonaalisen vasta-aineen valmistamiseksi ja vasta-ainetta tuottava hybridooma FI95043C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29031087 1987-11-17
JP62290310A JP2754206B2 (ja) 1987-11-17 1987-11-17 α２→３結合を認識するモノクローナル抗体

Publications (4)

Publication Number Publication Date
FI885279A0 true FI885279A0 (fi) 1988-11-15
FI885279A FI885279A (fi) 1989-05-18
FI95043B FI95043B (fi) 1995-08-31
FI95043C FI95043C (fi) 1995-12-11

Family

ID=17754449

Family Applications (1)

Application Number Title Priority Date Filing Date
FI885279A FI95043C (fi) 1987-11-17 1988-11-15 Menetelmä 2 3-sidoksen tunnistavan monoklonaalisen vasta-aineen valmistamiseksi ja vasta-ainetta tuottava hybridooma

Country Status (14)

Country Link
US (1) US5141864A (fi)
EP (1) EP0316882B1 (fi)
JP (1) JP2754206B2 (fi)
KR (1) KR960014441B1 (fi)
CN (1) CN1042734A (fi)
AT (1) ATE108482T1 (fi)
AU (1) AU624583B2 (fi)
CA (1) CA1337800C (fi)
DE (1) DE3850634T2 (fi)
FI (1) FI95043C (fi)
HU (1) HU204573B (fi)
IL (1) IL88400A (fi)
NO (1) NO173556C (fi)
NZ (1) NZ226974A (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
DE4208795A1 (de) * 1992-03-19 1993-09-23 Behringwerke Ag Monoklonaler anti-gangliosid-antikoerper, seine herstellung und verwendung als tumortherapeutikum
CN1057128C (zh) * 1993-09-22 2000-10-04 南通医学院 感觉神经抗体及其制备方法
US5674681A (en) 1994-12-06 1997-10-07 Rothenberg; Barry E. Methods to identify hemochromatosis
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
WO2004087911A1 (ja) * 2003-03-28 2004-10-14 Toyama New Industry Organization １個の抗原特異的ｂリンパ球を用いた抗原特異的抗体産生ハイブリドーマの作製方法及びモノクローナル抗体の製造方法
FI20070199A0 (fi) * 2007-03-08 2007-03-08 Glykos Finland Oy Uusia happamia N-glykaanirakenteita
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507391A (en) * 1982-04-02 1985-03-26 Sloan-Kettering Institute For Cancer Research Method for detecting the presence of GD3 ganglioside

Also Published As

Publication number Publication date
FI95043C (fi) 1995-12-11
CN1042734A (zh) 1990-06-06
AU624583B2 (en) 1992-06-18
EP0316882A2 (en) 1989-05-24
NO173556C (no) 1993-12-29
US5141864A (en) 1992-08-25
FI95043B (fi) 1995-08-31
AU2518688A (en) 1989-05-25
DE3850634D1 (de) 1994-08-18
NZ226974A (en) 1990-03-27
HUT48679A (en) 1989-06-28
IL88400A (en) 1993-06-10
NO885113L (no) 1989-05-18
KR960014441B1 (ko) 1996-10-15
NO885113D0 (no) 1988-11-16
CA1337800C (en) 1995-12-26
JPH01132374A (ja) 1989-05-24
HU204573B (en) 1992-01-28
EP0316882A3 (en) 1990-03-14
ATE108482T1 (de) 1994-07-15
EP0316882B1 (en) 1994-07-13
KR890008320A (ko) 1989-07-10
FI885279A (fi) 1989-05-18
JP2754206B2 (ja) 1998-05-20
IL88400A0 (en) 1989-06-30
NO173556B (no) 1993-09-20
DE3850634T2 (de) 1994-10-27

Similar Documents

Publication Publication Date Title
Brown et al. Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.
Frei et al. Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-CS antibodies
PT86792A (pt) Monoclonal antibodies against melanoma-associated antigens hybrid cell lines producing these antibodies and use therefor
ES498360A0 (es) Un metodo de preparacion de un anticuerpo monoclonal.
YU45068B (en) Process for obtaining a monoclonal antibody which is fixing a complement
FI885279A0 (fi) Menetelmä 2 3-sidoksen tunnistavan monoklonaalisen vasta-aineen valmistamiseksi ja vasta-ainetta tuottava hybridooma
NZ211989A (en) Monoclonal anticytomegalovirus antibodies and diagnostic system
DK392387D0 (da) Monoklonalt antistrof til diagnostisk anvendelse og fremgangsmaade til fremstilling af et saadan antistof
EP0251195A3 (en) Method and reagent for the determination of alpha-amylase
DE3875852D1 (de) Gereinigtes igm.
Matsuda et al. Carbohydrate binding specificity of monoclonal antibodies raised against lactose-protein Maillard adducts
Nilson et al. Cross-reacting monoclonal anti-α1-microglobulin antibodies produced by multi-species immunization and using protein G for the screening assay
FI873233A0 (fi) Modifierade virala glykoproteiner.
Mahana et al. Mice ascites as a source of polyclonal and monoclonal antibodies
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
US5443957A (en) Anti-asialo-GM1 monoclonal antibodies and method of use
FI860937A (fi) Menetelmä ja reagenssi follikkelia stimuloivan hormonin määrittämiseksi sekä tähän tarkoitukseen sopivat monoklonaaliset vasta-aineet
Dobbelaere et al. Production in ascites fluid of biosynthetically labelled monoclonal antibody to Theileria parva sporozoites
US5141865A (en) Monoclonal antibodies which bind thromboxane A2 receptor antagonists and diagnostic methods based thereon
US5898068A (en) Monoclonal antibodies which bind mevalonate kinase
HUT52564A (en) Process for production of gq under 1b and gt under la monoclonic antibodies capable to recognize gauglyosides
EP0190049A3 (en) Method for selecting hybridomas producing antibodies specific to inaccessible cell surface antigens
SU1721089A1 (ru) Штамм гибридных культивируемых клеток животных MUS.мUSсULUS L.-продуцент моноклонального антитела к глутаматным рецепторам мозга человека
Blancher et al. Anti‐human red cell monoclonal antibodies produced by macaque–mouse heterohybridomas: Their reactivity with human and nonhuman primate erythrocytes
Leibiger et al. Identification of carbohydrate structures of glycoproteins by a novel method utilizing a lectin-ELISA

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: MECT CORPORATION